iBio, Inc.

Contributing Author

Recent Articles by iBio, Inc.

Jun-24	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results IBIO GlobeNewswire
Jun-23	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call IBIO GlobeNewswire
Jun-16	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment IBIO GlobeNewswire
May-05	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model IBIO GlobeNewswire
May-02	iBio Reports Fiscal Third Quarter 2025 Financial Results IBIO GlobeNewswire